Relief Therapeutics Holding AG (RLFTF)

[go_wamu]

pegs1
Please keep Relief's answer to yourself. I can imagine what it says (I'm European!)
... but everyone should think about what Dr. JJ said on Twitter:

"Unfortunately that’s a disparaging myth and a blood fibel that damages the reputation of the most hardworking team I have ever been privileged to know.
As soon as the regulatory files are completed for transmission to FDA, they will be able to be available to European regulators as well. Anyone who thinks we would endanger patients, simply because of the financial behavior of a collaborator is sadly mistaken."

[????? !]... unfortunately he forgot that his hard work was paid for by Relief. IMO Dr. JJ is a cheater, who knew from the beginning how to act.
Of interest is the NIH-trial also, where ZYESAMI isn't mentioned in any case therein, but Aviptadil did so !

NIH-Trial: (last update April 26, 2021)
Brief Title: ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (TESICO)
Official Title: A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Responsible Party: Sponsor
Collaborators: International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)
Unversity of Copenhagen
Medical Research Council
Kirby Institute
Washington D.C. Veterans Affairs Medical Center
AIDS Clinical Trials Group
National Heart, Lung, and Blood Institute (NHLBI)
US Department of Veterans Affairs
Prevention and Early Treatment of Acute Lung Injury (PETAL)
Cardiothoracic Surgical Trials Network (CTSN)
NeuroRx, Inc.
Gilead Sciences

1) Experimental: Aviptadil + Remdesivir + SOC
Biological: Remdesivir
Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
Biological: Aviptadil
Administered by IV infusion over 12 hours per day for 3 days.
Other Names:
• Vasoactive Intestinal Peptide
• VIP
Drug: Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

2) Placebo Comparator: Aviptadil + Remdesivir Placebo + SOC
Drug: Remdesivir Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Biological: Aviptadil
Administered by IV infusion over 12 hours per day for 3 days.
Other Names:
• Vasoactive Intestinal Peptide
• VIP
Drug: Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

3) Experimental: Aviptadil Placebo + Remdesivir + SOC
Biological: Remdesivir
Administered by IV infusion, daily for 10 days. Initial loading dose is 200 mg with all subsequent doses 100 mg.
Drug: Aviptadil Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
Drug: Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

4) Experimental: Aviptadil Placebo + Remdesivir Placebo + SOC
Drug: Remdesivir Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion daily for 10 days.
Drug: Aviptadil Placebo
Commercially available 0.9% sodium chloride solution. Administered by IV infusion over 12 hours per day for 3 days.
Drug: Corticosteroid
In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.

Dr. JJ gave himself an advance .....
..... and he thinks he is right.
But the bill is to be paid at the very end !